CircRNAs, proteins, and metabolites, can act as upstream regulators of immunometabolic pathways. They also discuss how therapeutic loading of EVs could revolutionize treatment strategies in HF and related metabolic disorders.• Tu, D. et al. (2024) utilized machine learning and bioinformatics to re-analyze multiple microarray datasets, identifying a strong association between cuproptosis-related genes (CRGs) and the pathogenesis of HF. Their multivariable logistic regression models based on CRG expression suggest that cuproptosis modulates both metabolic and immune pathways in HF, offering potential diagnostic biomarkers and therapeutic targets.• Chen, J. et al. (2024) focused on diabetic heart failure, identifying four key CRGs (HSDL2, BCO2, CORIN, and SNORA80E) through bioinformatics analysis of GEO datasets. Among these, LOXL2 was most significantly linked to diabetic HF. The study also constructed an lncRNA-miRNA-mRNA network and predicted MECOM as a key transcription factor driving cuproptosis in cardiomyocytes, advancing our understanding of HF pathogenesis in diabetic patients.• Huang, Z. et al. (2024) examined factors contributing to accelerated aging in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). By analyzing clinical data from 216 patients, they developed phenotypic age acceleration (PhenoAgeAccel) metrics and identified several risk factors, including neutrophil count, urea, adenosine deaminase, and TyG index, while cholinesterase was identified as a protective factor. These findings underscore the clinical significance of aging-related biomarkers in T2DMassociated HF.• Jing, T. et al. (2024) investigated the prognostic impact of stress hyperglycemia in critically ill patients with cardiogenic shock using the MIMIC-IV database. Stratifying patients based on stress hyperglycemia ratio (SHR), they found that elevated SHR was associated with longer mechanical ventilation, extended ICU and hospital stays, and increased mortality. Their analysis suggests SHR may serve as a valuable prognostic indicator in this high-risk population.Collectively, these contributions illuminate the complex interplay between immune responses, metabolic alterations, non-coding RNAs, and extracellular vesicle signaling in the pathophysiology of heart failure. They also underscore the translational potential of targeting these pathways to develop novel diagnostics and therapeutic strategies.We anticipate that this Research Topic will serve as a comprehensive and insightful resource for researchers investigating the latest advances in immunometabolism and its therapeutic implications in cardiovascular disease.